Financial Data and Key Metrics Changes - Total revenue for Q4 2025 increased 65% year-over-year to $196 million, and for the full year increased 66% to $639 million [4][11] - Net product sales of Auvelity for Q4 were $155.1 million, up 68% compared to the prior year, and total sales for Auvelity reached $507.1 million for the full year, representing a 74% year-over-year increase [12][15] - Net loss for Q4 was $28.6 million, or $0.56 per share, compared to a net loss of $74.9 million, or $1.54 per share for Q4 2024 [15] - Net loss for the full year of 2025 was $183.2 million, or $3.68 per share, compared to a net loss of $287.2 million, or $5.99 per share for 2024 [16] Business Line Data and Key Metrics Changes - Auvelity achieved sales of over $500 million in its third full year of launch, with significant growth contributing to overall revenue [4] - Sunosi generated net product revenue of $36.7 million for Q4, a 40% increase compared to Q4 2024, and $124.8 million for the full year, representing a 32% increase [12] - Symbravo generated $4.1 million in net sales for Q4 and $6.6 million for the full year, following its second full quarter of launch [12] Market Data and Key Metrics Changes - Auvelity prescriptions grew by 42% year-over-year, with over 225,000 prescriptions written in Q4 [18] - Payer coverage for Auvelity increased from 75% to 78%, bringing total coverage to 86% of all lives across channels [19] - Symbravo's overall payer coverage is approximately 52% at the start of the year, with 49% in commercial and 57% in government channels [21] Company Strategy and Development Direction - The company is advancing a broad CNS pipeline with 5 novel product candidates across 9 high-impact indications, including a planned phase 2/3 trial of AXS-05 in smoking cessation [5][6] - AXS-12's NDA submission for narcolepsy is expected imminently, with significant progress made following positive FDA pre-NDA meeting minutes [6] - The company plans to expand its sales force to approximately 600 representatives to support growth in MDD and potential Alzheimer's disease agitation [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver upon vast opportunities for the growing portfolio of CNS medicines, supported by a scalable commercial platform [4][18] - The company anticipates continued momentum in its commercial business and expects to generate significant value through disciplined investment and performance across its CNS portfolios [104] Other Important Information - The company ended the year with $323 million in cash and cash equivalents, compared to $315 million at the end of 2024, indicating sufficient funds to support operations into cash flow positivity [17] - Gross and net discounts for Auvelity and Sunosi are expected to increase due to typical Q1 dynamics, with Symbravo's gross net discount remaining elevated during the launch phase [13] Q&A Session Summary Question: Implications of the new FDA publication on the one trial policy - Management is assessing the implications and will continue to vet clinical plans with the FDA, indicating potential for supportive evidence in ongoing studies [26][27] Question: Development plan for AXS-17 in epilepsy - The product has been studied in various indications, and the company is closely assessing different types of epilepsy for potential clinical success [31][33] Question: Auvelity payer coverage evolution post-ADA label addition - Existing coverage is expected to apply to the new indication, with efforts ongoing to ensure sufficient coverage and utilization management [35][36] Question: Initial launch cadence for Alzheimer's agitation - The company is preparing for a launch within a quarter post-approval, with metrics to be shared regarding script percentages from the ADA space [39][69] Question: Growth drivers for Sunosi - Growth is driven by both volume and improved access, with steady performance in both OSA and narcolepsy markets [44] Question: DTC campaign progress for Auvelity - The national TV campaign launched in late 2025 has generated positive impacts on new patient starts, with ongoing optimization of media spend [46][48] Question: Coverage expectations for Auvelity at steady state - The goal is to secure access for as many patients as possible, with steady progress in increasing covered lives anticipated [50][52] Question: AXS-12 opportunity in narcolepsy - AXS-12 offers compelling treatment options for patients, with strong data in cataplexy and potential benefits in excessive daytime sleepiness [72][74]

Core Insights - Bond, Inc. has established a phase 1 commercial agreement valued at approximately $250,000 with a major pharmaceutical company, marking a significant step in its revenue growth strategy [2][3] - The agreement covers 5,000 employees and has the potential to expand the contract value beyond $1 million over time, indicating strong growth prospects for Bond's services [3][4] Revenue Growth - The $250,000 agreement contributes to Bond's Annual Recurring Revenue (ARR) and reflects ongoing traction within large multinational enterprises [5] - Initial enterprise engagements are viewed as foundational relationships that can lead to broader adoption and scalable ARR growth within large organizations [5] Strategic Importance - Executing agreements with global leaders is central to Bond's expansion and revenue growth strategy, aiming to establish a standard for corporate security [6] - The company anticipates that initial coverage will expand to include more employees over time, positioning Bond as a potential global standard for preventative security [6] Versatility and Market Potential - Bond's AI-powered platform is designed to address diverse workforce protection challenges across various employee functions and geographies, enhancing its applicability [7] - The platform's effectiveness, scalability, and affordability contribute to a significant Total Addressable Market (TAM), potentially reaching anyone with a connected device [8] Industry Recognition - Bond has been recognized as a sole supplier of AI-Powered Preventative Personal Security, which streamlines its market entry and reduces competitive tender processes [8] - The company has supported over 1.4 million security service requests, demonstrating its operational effectiveness and growing trust among corporations and public entities [11]

And now I'd like to welcome in Kevin Green who's joining me to help me set up the action today. And so KG, as far as last week, I mean it was a busy week. I I had a guest call it as like markets are tired and I was like I think that I am as well.We have a new week to kick things off of course a full week. We had a holiday short and trading week last week. What are you watching this week. What are your key assessments from last week.>> Yeah, Jenny, I would actually agree. If you kind of look at the technical ...

TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced that it has executed a binding supply agreement with Amsterdam University Medical Center (“Amsterdam UMC”) in the Netherlands for the provision of LaNeo™ 40mg MDMA capsules for use in a proposed clinical trial. Under the terms of the agreement, PharmAl ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Core Insights - Voyageur Pharmaceuticals Ltd. has signed a collaboration and funding agreement with Bayer, providing milestone-based funding support of up to USD 2.35 million to develop iodine for medical imaging contrast media [1][2][3] Company Developments - The agreement includes an initial payment of USD 350,000 upon execution, USD 1,000,000 upon commencement of a feasibility study for an iodine extraction plant in Oklahoma, and another USD 1,000,000 upon completion of the study [3] - Voyageur has acquired iodine intellectual property from Dr. Brian Mueller, positioning the company to be a key player in the global iodine supply chain [1] - The company aims to become the first domestic producer of iodine contrast media in the United States, enhancing the security of the North American healthcare supply chain [4][7] Project Details - Voyageur is working on feasibility studies for both the Bayer project and its own radiology drug production project, which includes producing barium contrast drugs from its Frances Creek project in British Columbia and iodine contrast media from the Anadarko basin in the USA [5][6] - Initial lab bench testing for the Bayer project has been completed, and the company plans to build a small transportable field unit to gather data for the feasibility study [6] Market Context - The global contrast media market was valued at USD 6.77 billion in 2024 and is projected to reach USD 13.86 billion by 2033, growing at a CAGR of 8.3% from 2025 to 2033 [8] - North America accounts for approximately 39.07% of the global iodine contrast media market, valued at USD 2.65 billion annually due to high imaging volumes [8] Strategic Vision - Voyageur aims to vertically integrate the barium and iodine contrast markets, controlling all primary input costs from sourcing raw materials to final production [10][13] - The company plans to transition into a high-margin domestic manufacturer of radiology drugs, ensuring product validation by regulatory agencies worldwide [11]

Company Overview - Proactive is a financial news and online broadcast organization that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates across key finance and investing hubs with offices in London, New York, Toronto, Vancouver, Sydney, and Perth [2] Content Production - Proactive's editorial team produces approximately 50,000 pieces of real-time news, feature articles, and filmed interviews annually [1] - The content covers a wide range of topics, including medium and small-cap markets, blue-chip companies, commodities, biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is committed to adopting technology to enhance workflows, utilizing both human expertise and technological tools [4] - The company employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain quality and best practices in content production [5]

Core Insights - Gossamer Bio's experimental drug for a serious lung and heart condition failed to meet the primary endpoint in a late-stage clinical trial [1] Company Summary - Gossamer Bio announced the failure of its experimental drug in a late-stage study, which is a significant setback for the company [1]

Core Insights - The European Commission has approved subcutaneous (SC) amivantamab, allowing for administration in minutes rather than hours, with efficacy and safety consistent with intravenous (IV) amivantamab [1][2][3] - SC amivantamab is now authorized for all previously approved IV indications, including every-four-week (Q4W) and every-three-week (Q3W) dosing regimens for advanced non-small cell lung cancer (NSCLC) [1][2][3][4] - The new dosing options aim to reduce administration-related reactions and improve patient convenience [1][2][3][4] Company Developments - Johnson & Johnson announced the approval of SC amivantamab, which is expected to enhance the treatment experience for patients with EGFR-mutated NSCLC [1][2][3] - The approval is part of Johnson & Johnson's commitment to improving patient care and treatment flexibility [1][2][3] Clinical Study Results - The approval is supported by Phase 2 PALOMA-2 and Phase 1 PALOMA studies, which demonstrated that SC amivantamab has a response rate and safety profile similar to IV amivantamab, but with significantly fewer administration-related reactions [1][2][3][4] - Administration time for SC amivantamab is approximately five minutes, compared to five hours for the first IV infusion [1][2][3][4] Treatment Context - Amivantamab is a bispecific antibody targeting EGFR and MET mutations, which are prevalent in NSCLC [3][4] - The approval of SC amivantamab aligns with the growing need for more efficient treatment options in the context of lung cancer, which is the leading cause of cancer-related deaths in Europe [6][7]

Core Insights - Dividend stocks and Consumer Staples experienced losses or flat prices last week, with Crown Castle and AbbVie among the biggest decliners, while Coca-Cola outperformed due to positive Wall Street research notes [1] Group 1: Company Performance - Crown Castle (CCI) saw a significant decline after terminating its agreement with DISH Wireless due to a default on payment obligations, leading to a potential $3.5 billion revenue shortfall and an expected net loss of $780 million in 2026 [1] - AbbVie (ABBV) dropped nearly 3% despite FDA approvals for its drug, facing headwinds from broader healthcare sector weakness and drug pricing policy uncertainties [1] - AT&T (T) fell approximately 2.5% after two banks lowered their price targets, reflecting concerns about the competitive telecom environment, particularly with T-Mobile's new service [1] Group 2: Dividend Changes - Crown Castle reduced its quarterly dividend from $1.565 to $1.0625 per share, raising questions about the sustainability of its dividend amid financial challenges [1] - AbbVie has increased its dividend for 13 consecutive years, with the latest quarterly dividend at $1.73 per share, reflecting a 5.5% increase from the previous rate [1] - AT&T maintains a quarterly dividend of $0.2775 per share, yielding close to 4% at current prices, but faces limited near-term upside according to analyst consensus [1] Group 3: Market Trends - The Schwab U.S. Dividend Equity ETF was flat, while the Consumer Staples SPDR fell by 1.8%, indicating a pause in the performance of dividend stocks [1] - The VIX index is at 20.23, indicating a boundary between normal and elevated uncertainty, while the 10-year Treasury yield is at 4.08%, down from 4.29%, providing some relief for rate-sensitive dividend stocks [2] - Overall, 2026 has been a strong year for dividend stocks, with investors seeking stability amid market volatility [2]